Sinusitis is an inflammation of the paranasal sinuses that causes nasal congestion, pain, and breathing difficulties. According to J. Mullol et al., 2024, the global prevalence of chronic rhinosinusitis (CRS) ranges from 5% to 12%, with nearly 20% of cases involving nasal polyps. According to the Sinusitis Pipeline Analysis by Expert Market Research, the market is witnessing strong growth driven by advancements in biologics, corticosteroids, and antibiotic therapies. The increasing focus on targeted drug delivery, innovative formulations, and precision medicine is expected to enhance treatment outcomes and propel the sinusitis drug pipeline in the coming years.
The Sinusitis Pipeline Report by Expert Market Research gives comprehensive insights into sinusitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for sinusitis. The sinusitis pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from sinusitis.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing sinusitis pipeline development activities related to sinusitis are covered.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Sinusitis is the swelling or inflammation of the tissue lining the sinuses. Sinuses are parts inside the face which are normally filled with air. The infections like bacterial infections, viral infections and allergies can irritate them, and cause them to get blocked and filled with fluid. This creates pressure, pain in the face, and nasal congestion among other symptoms. There are multiple types of sinusitis such as acute, subacute, chronic, and recurrent sinusitis, bacterial and viral sinusitis, and fungal sinusitis. The common symptoms of the disease are postnasal drip, stuffy nose, runny nose with thick green or yellow mucus, facial pressure, pressure or pain in the ear, teeth, fever, cough, headache, and tiredness, among others.
Common sinusitis drugs include decongestants, over-the-counter cold and allergy medications, nasal saline rinses and drinking plenty of fluids among others. Chronic sinusitis is treated by topical antihistamine sprays or oral pills, intranasal steroid sprays, leukotriene antagonists, like montelukast and surgeries among others. Other sinusitis therapeutic drugs given to treat the disease include augmentin, amoxicillin, levofloxacin, doxycycline, cefpodoxime, cefixime, and clindamycin among others.
Several pharma companies and institutes are developing innovative treatments to manage sinusitis. For instance, in January 2024, Optinose, a pharmaceutical company announced the publication of a reopened phase III clinical trial program which evaluated xhance for the treatment of adults with chronic sinusitis. This unique product combines nasal anti-inflammatory drugs with the exhalation delivery system. Several innovative sinusitis drug candidates are currently in the pipeline which is being developed by major pharma companies and institutions, impacting the sinusitis pipeline analysis.
This section of the sinusitis report covers the analysis of sinusitis drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s sinusitis therapeutic assessment report covers 50+ drug analyses based on molecule classes:
By Route of Administration
EMR’s sinusitis clinical assessment report covers 50+ drug analyses based on the route of administration.
The sinusitis report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for sinusitis.
The drug molecules categories covered under sinusitis pipeline analysis include antibody, antisense oligonucleotides, immunotherapy, monoclonal antibody, peptides, protein, recombinant protein, small molecule, stem cell and vaccine. Several monoclonal antibodies have shown a positive impact on the treatment process for sinusitis. Dupilumab is another monoclonal antibody which has been proven effective in managing allergies. It reduces inflammation and helps in preventing the formation of nasal polyps. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for sinusitis.
The EMR sinusitis report insights for the sinusitis drug pipeline cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in sinusitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for sinusitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of sinusitis drug candidates.
The trial is designed to evaluate the safety and effectiveness of two antibiotic regimens in acute bacterial sinusitis treatment. The trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and is currently under phase III.
The objective of the study is to assess the effects of SINUclean DM spray. This spray is added to the standard therapy for sinusitis. The study is being conducting to check the safety of spray and whether it is capable to determine the resolution of the symptoms in a shorter time.
Bayer is developing the sinusitis drug candidate and it is currently under phase III. The study is being conducted to assess the safety and effectiveness of Avelox in a 5-day treatment of adult patients having acute bacterial sinusitis.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Sinusitis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for sinusitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into sinusitis collaborations, market trends, regulatory environments, and potential growth opportunities within sinusitis pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share